Just because LC said Hervaxx is in a crowded space does not mean that it is a dead duck. Basically what LC means is that in this space, Hervaxx needs to prove that it is far better than the rest. And since it is a crowded space, just takes a bit longer to stand out. And stand out it will because there is NOTHING with its kind of safety profile. And as far as efficacy is concerned, it is as good, if not better than Herceptin which is currently the best out there.
On the other hand, Checkvacc, Vaxinia and OnCarlytics are in very sparse space. Just any sign of good efficacy with great safety profile, and it would be game on. Not long to go now with this, as far as biotech term is concerned.
Media Thread, page-7498
-
- There are more pages in this discussion • 8,226 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $356.9M | |||
| Open | High | Low | Value | Volume |
| 4.9¢ | 4.9¢ | 4.8¢ | $328.5K | 6.792M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 45 | 5443565 | 4.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.9¢ | 2171910 | 5 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| IMU (ASX) Chart |